产品描述
| 溶解性 | DMSO |
| 存贮条件 | 储存温度-20°C |
| 产品介绍 | NVP-LCQ195 (AT9311; LCQ195)是CDK杂环类抑制剂，对CDK1，CDK2，CDK3和CDK5的IC50为1-42 nM。 |
| 生化机理 | NVP-LCQ195 (AT9311; LCQ195) is a small molecule heterocyclic compound which inhibits CDK1, CDK2 and CDK5, as well as CDK3 and CDK9. Cell cycle regulators, such as cyclin-dependent kinases (CDKs), are appealing targets for multiple myeloma (MM) therapy given the increased proliferative rates of tumour cells in advanced versus early stages of MM. NVP-LCQ195 induced cell cycle arrest and eventual apoptotic cell death of MM cells, even at sub-μmol/l concentrations, spared non-malignant cells, and overcame the protection conferred to MM cells by stroma or cytokines of the bone marrow milieu. |
| 别名 | LCQ-195;AT-9311;NVP LCQ195;LCQ 195;AT9311;AT 9311；4-(2,6-二氯苯甲酰基氨基)-1H-吡唑-3-羧酸 N-[1-(甲基磺酰基)哌啶-4-基]酰胺;LCQ-195;AT-9311;NVP LCQ195;LCQ 195;AT9311;AT 9311；4-(2,6-Dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid N-[1-(methylsulfonyl)piperidin-4-yl]amide |
